NCT06028633

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with platinum-doublet chemotherapy. All participants will be given with albumin-bound paclitaxel, lenvatinib and pembrolizumab.

Conditions

• Advanced Non-squamous Non-small-cell Lung Cancer
• Recurrent Non-Squamous Non-Small Cell Lung Cancer
• Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	pembrolizumab	pembrolizumab 200mg IV on day 1 for every 3 weeks
DRUG	lenvatinib	lenvatinib 8mg taken orally every day
DRUG	albumin-bound paclitaxel	albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-10-01
• Completion: 2026-10-01
• First posted: 2023-09-08
• Last updated: 2023-09-13

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study